At #ASCO2026, we continued our tradition of bringing together our patient advocacy organizations and professional societies to kick off ASCO with connection, dialogue, and shared purpose.
Thank you to the leaders who spent time with us. Your perspectives and continued advocacy help guide how we think, collaborate, and work toward more patient-centered approaches.
#PatientAdvocacy
During this edition of #AntibodyHour 🕙, patient advisor Linda Emery shares her experience and encourages others to see clinical trials differently; not as a final option but as an opportunity worth exploring.
Her story is a reminder during Clinical Trial Awareness month of the importance of awareness and understanding the potential of clinical research.
Learn more about our impact: https://t.co/6d2RfYwRyX
#Innovation #PatientFirst #ClinicalTrialAwarenessMonth
#NewsUpdate: We’re looking forward to presenting new data in #BloodCancer at #ASCO2026 and #EHA2026, with 20 abstracts showcasing our latest investigational treatment innovations across a range of B-cell malignancies.
Learn more: https://t.co/AHOBISMUrV
By 2050, #ovariancancer diagnoses are projected to rise by more than 55%, impacting over half a million women globally (1).
On #WorldOvarianCancerDay, we stand with the global community to drive awareness, earlier diagnosis, and improved care.
1 Global Cancer Observatory (GCO). International Agency for Research on Cancer, World Health Organization. Estimated numbers from 2022 to 2050, females aged 0–85+.
#InvestorUpdate: Genmab has published its first-quarter interim report. Hear from our executive leaders about the progress we have made in our late-stage pipeline of innovative antibody products and key business milestones achieved this quarter.
Learn More: https://t.co/1DNKHPfLPB.
#Innovation #Biotech
Genmab is proud to support the next generation of life-science innovators by sponsoring the Life Science Award at the Danish Entrepreneurship Championship.
Congrats to this year’s winners SundtGear, who created supportive tights with built-in elastic assist to help elderly users stand up safely.
Learn more about how we support our community here: https://t.co/walsmT6ysQ.
#LifeScience #Entrepreneurship
Recently, we celebrated our colleagues Amy Whited, Mande Ye, and Laura Højland Larsen who were recognized by @HBAnet as Luminaries and Rising Star at the Woman of the Year event! We congratulate you and thank you for your leadership and impact.
#HBAWOTY2025
Our U.S. based colleagues celebrated #TakeYourChildToWorkDay by welcoming very special guests to Genmab for a day of discovery and learning about finance through a bake sale, making picture frames for children coping with the loss of a parent, building bee boxes to support sustainability, as well as participating in engaging sessions on brand marketing, AI and pathology.
We loved sharing what we do, and why it matters with the next generation.
Head and neck squamous cell carcinoma (HNSCC) can be challenging to treat and can profoundly affect everyday activities, including speaking, swallowing, and interacting with others (1). That’s why awareness, education, and collaboration matter for people living with the disease. Genmab stands with the community and partners working to close gaps in awareness and care. #HeadandNeckCancerAwareness
1 McCartney J. Rising incidence of head and neck cancer drives treatment advances. Bull Am Coll Surg. October 2025;110(9). https://t.co/IXL2tT7dXH
For many, the fight against head and neck cancer begins with uncertainty and can have profound impacts on daily life. Clear information, compassionate care, and strong support can make a real difference.
Genmab is proud to stand with patients, care partners, and advocates to develop innovative antibody-based medicines in areas of critical need.
#HeadandNeckCancerAwareness #HNSCC
What does it mean to lead with vision, drive innovation, and move faster for patients who can’t wait?
Real innovation means challenging convention, embracing new ideas, and collaborating with the ambition to deliver meaningful progress for patients.
Learn what our colleagues have to say about turning these ideas into action.
Thanks to @BioNJ for the original footage produced by @KenBlando at Pulse Productions Inc.
#Leadership #Innovation
At #SGO2026, we shared new safety data supporting the combination potential of one of our investigational agents in recurrent #OvarianCancer. Results add to the growing body of clinical evidence for this program and its potential to expand treatment options for patients.
Visit: https://t.co/tEJ8VBjdwr.
From bold antibody discovery to breakthrough innovation — this is Genmab.
Learn how we’ve evolved from designing next-generation antibodies to taking greater ownership of their journey from discovery, through development, and all the way to the patients who need them most.
Watch the full video to see how we’re leading antibody science for better futures here: https://t.co/kdnBWgQoyq.
#AntibodyScience
Inside Antibody Innovation: What’s Next?
In this #AntibodyHour 🕙, we spotlight the people driving our innovation. Hear from Patrick Engelberts, Associate Director, Product Discovery at Genmab, on how we’re advancing the natural precision of antibodies.
From target specificity to binding strength, every detail shapes next-gen therapeutics. As the science advances, so does our ambition to continuously improve and apply the latest innovations with the goal of benefitting patients.
Learn more about our science: https://t.co/5ZqCCnNMYT.
#Biotech #Innovation
Genmab has been awarded Finansforeningen’s Special Prize 2025, selected unanimously by the Accounting Committee for our open, timely, and consistent investor communication.
Finansforeningen (CFA Society Denmark) is a Danish professional association for finance and investment professionals.
Thank you to our investors and stakeholders for the continued trust, and to our teams who work with the goal of making a difference for patients through antibody medicines.
Learn more: https://t.co/ReR35bHCfM.
#InvestorRelations
#InvestorUpdate: Today, Genmab held its 2026 Annual General Meeting.
Our CEO Jan van de Winkel and CFO Anthony Pagano presented Genmab’s 2025 Annual Report.
For more information, visit: https://t.co/Dybmrr347l.
"I believe breakthrough science can be a miracle for a patient and her family.” - Robin Cohen
Tune in to this edition of #AntibodyHour 🕙 to hear from Robin Cohen, BSN, CEO of the Sandy Rollman Ovarian Cancer Foundation, as she shares how a patient’s final words shaped her mission.
Robin reminds us that “a win” looks different for every patient. Some ask, “How long will I live?” Others ask, “How will I live?” Those questions challenge all of us as scientists, clinicians, and colleagues to focus on what truly matters to each individual patient and their family. At Genmab, stories like these are grounding. They remind us why breakthrough science and urgency matter, and why every antibody we work on carries our aspiration to transform the lives of patients.
#PatientFirst
In honor of International Women’s Day, we were pleased to welcome Courtney Clark for a special keynote on building resilience and navigating change, through what she refers to as revisionary thinking. The session includes reflection facilitated by Amy Whited and Leslie Amendola.
Genmab is also making a donation to @WomanspaceInc, a secure space for women, as part of our commitment to making a positive impact in the communities where we live and work.
#CommunityatGenmab #InternationalWomensDay